Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren

NCT03648827 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT03648827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03648827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Lead sponsor
PTC Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 21, 2018
Completion date
October 23, 2020
Enrollment
20 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy